SAGE Therapeutics Inc. (SAGE)

159.79
NASDAQ : Health Technology
Prev Close 160.90
Day Low/High 159.02 / 162.91
52 Wk Low/High 79.88 / 193.56
Avg Volume 359.10K
Exchange NASDAQ
Shares Outstanding 51.65M
Market Cap 8.31B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Sage Therapeutics Not In M&A Discussions: STATEMENT

Sage Therapeutics (NASDAQ: SAGE) - On February 16, 2017, Chief Executive Officer Jeff Jonas conducted an interview about SAGE-217 in major depressive disorder (MDD).

Sage Therapeutics Lifts Investor Spirits With Sliver of Depression Drug Data

Sage Therapeutics Lifts Investor Spirits With Sliver of Depression Drug Data

Depression represents a huge commercial market opportunity. It's also a disease in which drugs that show impressive results in early studies routinely flame out before reaching the finish line.

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.

Sage Therapeutics Advances SAGE-217 Into Placebo-Controlled Phase 2 Clinical Trial In Major Depressive Disorder

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced encouraging top-line results from...

Sage Therapeutics To Participate In Upcoming February Investor Conferences

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it will participate in the...

Sage Therapeutics To Present At J.P. Morgan Healthcare Conference On Tuesday, January 10, 2017

Sage Therapeutics To Present At J.P. Morgan Healthcare Conference On Tuesday, January 10, 2017

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company is scheduled...

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Starbucks, Allergan, Amazon: Doug Kass' Views

Starbucks, Allergan, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on how 2017 will be the year of 'the Dude.'

Sage Therapeutics To Participate In Goldman Sachs Healthcare Conference

Sage Therapeutics To Participate In Goldman Sachs Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

Sage Therapeutics Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Mood Disorders

Sage Therapeutics Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Mood Disorders

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the initiation of Phase 2 clinical...

Allergan, Apple, Oakland Capital: Doug Kass' Views

Allergan, Apple, Oakland Capital: Doug Kass' Views

Doug Kass shares his thoughts on China and life insurers.

Sage Therapeutics Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Movement Disorders

Sage Therapeutics Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Movement Disorders

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the initiation of Phase 2 clinical...

Facebook, Apple, Starbucks: Doug Kass' Views

Facebook, Apple, Starbucks: Doug Kass' Views

Doug Kass shares his thoughts on managing and selecting short-term trades.

Sage Therapeutics To Webcast R&D Day On December 13, 2016

Sage Therapeutics To Webcast R&D Day On December 13, 2016

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it will webcast its R&D...

Sage Announces Expedited Development Plan For SAGE-547 In The Treatment Of Postpartum Depression Based On FDA Breakthrough Therapy Meeting

Sage Announces Expedited Development Plan For SAGE-547 In The Treatment Of Postpartum Depression Based On FDA Breakthrough Therapy Meeting

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced its expedited development plan for...

Apple, Starbucks, Cisco: Doug Kass' Views

Apple, Starbucks, Cisco: Doug Kass' Views

Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'

Sage Therapeutics To Present At American Epilepsy Society 70th Annual Meeting

Sage Therapeutics To Present At American Epilepsy Society 70th Annual Meeting

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at...

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about how Apple is still a short for him and that the market is still resistant.

Facebook, Home Depot, Disney: Doug Kass' Views

Facebook, Home Depot, Disney: Doug Kass' Views

Doug Kass shares his thoughts on contrariness and his takeaways and observations on the market.

SAGE-547 Granted PRIME Designation By EMA For The Treatment Of Postpartum Depression

SAGE-547 Granted PRIME Designation By EMA For The Treatment Of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the European Medicines...

Allergan, Macy's, Apple: Doug Kass' Views

Allergan, Macy's, Apple: Doug Kass' Views

Doug Kass shares his thoughts on closed-end municipal bond funds.

Sage Therapeutics To Present At Society For Neuroscience 2016 Annual Meeting

Sage Therapeutics To Present At Society For Neuroscience 2016 Annual Meeting

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at the...

Sage Therapeutics To Present At The Stifel 2016 Healthcare Conference

Sage Therapeutics To Present At The Stifel 2016 Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

Cisco, Allergan, Facebook: Doug Kass' Views

Cisco, Allergan, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.

Friday Wasn't Bad; Amazon-Induced Woes: Best of Kass

Friday Wasn't Bad; Amazon-Induced Woes: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about Friday's positives and retail's woes.

CORRECTING and REPLACING Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update

CORRECTING and REPLACING Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update

In the section Expected Near-Term Clinical Milestones, under Trial Initiations, the fourth bullet should read "Sage-217 in MDD" (instead of "Sage-547").

Sage Therapeutics To Report Third Quarter 2016 Financial Results On Thursday, November 3, 2016

Sage Therapeutics To Report Third Quarter 2016 Financial Results On Thursday, November 3, 2016

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

Sage Reports Additional Positive Data On Secondary Endpoints From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression At The Marcé Society For Perinatal Mental Health Biennial Scientific Meeting

Sage Reports Additional Positive Data On Secondary Endpoints From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression At The Marcé Society For Perinatal Mental Health Biennial Scientific Meeting

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced positive results on secondary endpoints from...

Sage Therapeutics To Present At The Leerink Partners Rare Disease Roundtable

Sage Therapeutics To Present At The Leerink Partners Rare Disease Roundtable

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

TheStreet Quant Rating: D (Sell)